BDSX vs. DCGO, SERA, QIPT, BNR, CORBF, EUDA, PIII, ATPC, BMGL, and MRAI
Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include DocGo (DCGO), Sera Prognostics (SERA), Quipt Home Medical (QIPT), Burning Rock Biotech (BNR), Global Cord Blood (CORBF), EUDA Health (EUDA), P3 Health Partners (PIII), Agape ATP (ATPC), Basel Medical Group (BMGL), and Marpai (MRAI). These companies are all part of the "healthcare" industry.
Biodesix vs. Its Competitors
Biodesix (NASDAQ:BDSX) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.
In the previous week, DocGo had 1 more articles in the media than Biodesix. MarketBeat recorded 6 mentions for DocGo and 5 mentions for Biodesix. Biodesix's average media sentiment score of 0.62 beat DocGo's score of 0.53 indicating that Biodesix is being referred to more favorably in the media.
21.0% of Biodesix shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 30.1% of Biodesix shares are held by company insiders. Comparatively, 3.8% of DocGo shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Biodesix has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, DocGo has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.
DocGo has higher revenue and earnings than Biodesix. DocGo is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.
DocGo has a net margin of -4.20% compared to Biodesix's net margin of -53.66%. DocGo's return on equity of -3.26% beat Biodesix's return on equity.
Biodesix presently has a consensus price target of $32.50, indicating a potential upside of 339.19%. DocGo has a consensus price target of $3.24, indicating a potential upside of 154.92%. Given Biodesix's stronger consensus rating and higher possible upside, equities analysts clearly believe Biodesix is more favorable than DocGo.
Summary
DocGo beats Biodesix on 8 of the 15 factors compared between the two stocks.
Get Biodesix News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodesix Competitors List
Related Companies and Tools
This page (NASDAQ:BDSX) was last updated on 10/13/2025 by MarketBeat.com Staff
